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The purpose of this study was to evaluate the surgical outcome of 
COmpletion thyroidoctomy in patients with presumed unilateral well- 
differentiated thyroid cancer (WDTC). The medical records of all patients 
having had unilateral thyroid Iobectomy for WDTC, who subsequently 
Underwent completion thyroidectomy, were reviewed. From 1980 to 1991, 
60 patients with WDTC underwent completion thyroidectomy. Forty- 
seven patients had presumed unilateral WDTC, with no evidence of 
residual disease prior to their completion thyroidectomy. Twenty-five 
(53%) of these patients were found to have residual neoplastic disease in 
the neck. In 20 (43%) of 47 patients, a focus of cancer was found in the 
remaining thyroid lobe and in 5 additional patients no cancer was found 
In the contralateral lobe, however, unsuspected nodal disease was found. 
The remaining 13 of the 60 patients presented with either regional 
recurrence (n = 12) or distant metastases (n = 1) at the time of their 
~ Ompletion thyroidectomy. All (92 %) hut I of these 13 patients had cancer 
u the remaining thyroid lobe. Multifocal disease in the primary lobe was 
aSsociated with bilateral thyroid cancer (p < 0.01). Complications were 
infrequent; transient hypocalcemia occurred in 5 (8%) patients, perma- 
nent hypoparathyroidism occurred in 1 (1.7%) patient, and transient 
recurrent laryngeal nerve palsy occurred in 3 (5%) patients. Residual 
WDTC was found in 37 (62%) of 60 patients undergoing completion 
thyroidectomy. Multifocal disease in the primary resected lobe was 
aSSociated with a high incidence of contralateral thyroid cancer. Comple- 
tion thyroidectomy is a safe procedure and may prevent the development 
of regional recurrence by eliminating an unsuspected focus of cancer. 
The extent of primary surgical resection for well-differentiated 
thyroid cancer (WDTC) remains controversial. Some surgeons 
advocate unilateral lobectomy on the affected side, claiming no 
difference in survival when compared to bilateral thyroidec- 
tomy [1-4]. A decreased morbidity is claimed in patients 
Undergoing an unilateral thyroidectomy when compared to 
Patients undergoing a total or near-total thyroidectomy [1-4]. 
Others have recommended a subtotal thyroidectomy for the 
management of WDTC, removing all of the affected lobe, 
tSthmus and part of the contralateral lobe [5-7]. The rationale 
for such an approach has been that there is a decreased rate of 
local recurrence in these patients, when compared to patients 
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who have undergone an unilateral procedure. Finally, there are 
those who advocate total or near-total thyroidectomy for pa- 
tients with WDTC [8-15]. Total thyroidectomy for WDTC has 
several advantages [ 16]. First, complete removal of the thyroid 
gland facilitates the detection, and ablation of metastatic dis- 
ease with radioactive iodine [17]. Second, thyroglobulin levels 
are more useful indicators of recurrent disease when nearly all 
normal thyroid tissue has been eliminated [17-19]. Third, the 
removal of all thyroid tissue eliminates the small chance of 
residual WDTC undergoing anaplastic transformation [17]. 
Fourth, a recent study suggests that there is an improved 
survival and decreased recurrence rate in patients who have 
undergone a total or near-total thyroidectomy for WDTC [15]. 
Finally, a total thyroidectomy eliminates both the primary 
tumor and any potential residual contralateral cancer. The 
incidence of this occurring has been reported to be as high as 
88% [11]. 
Although surgeons and endocrinologists may disagree on the 
ideal primary procedure for unilateral WDTC, most however, 
would agree that all thyroid tissue containing thyroid cancer 
should be removed. The problem arises when one is presented 
with the patient who has undergone a lobectomy for a thyroid 
nodule and in whom the diagnosis of cancer was not made until 
after the operation. Under these circumstances, re-operation is 
required to remove all remaining thyroid tissue, including any 
unsuspected contralateral foci of WDTC. Many surgeons have 
argued that the increased morbidity of re-operative thyroid 
surgery is too high to justify such a procedure [20]. At the 
University of Michigan, we advocate total thyroidectomy for 
WDTC, and recommend completion thyroidectomy for all 
patients with clinically significant WDTC (tumors >1.0 cm) 
who have significant residual thyroid tissue remaining in the 
neck. Significant residual thyroid tissue is defined as thyroid 
tissue capable of ~31I uptake >5% over 24 hours. However, for 
the purposes of this study, we limited our study population to 
those patients who had undergone a unilateral thyroid resection 
for WDTC. The purpose of this study was to examine the 
outcome of completion thyroidectomy in patients with pre- 
sumed unilateral WDTC. Specifically, we wished to determine 
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the incidence of residual disease and the complication rate of 
re-operation. 
Methods 
Medical records of all patients who underwent completion 
thyroidectomy at the University of Michigan Medical Center 
(UMMC) following Iobectomy for WDTC from 1980 to 1991 
were reviewed. During this period, 60 (21%) of the 284 patients 
with WDTC treated at the UMMC underwent completion 
thyroidectomy as a second procedure. A previous unilateral 
lobectomy was performed for a solitary thyroid nodule with no 
clinical evidence of disease by preoperative or intra-operative 
palpation on the contralateral side in each of these patients. The 
population under study was divided into two groups. Group 1 
underwent prophylactic completion thyroidectomy in the ab- 
sence of any clinical evidence of either residual, recurrent, or 
metastatic disease. Group 2 patients underwent therapeutic 
completion thyroidectomy after presenting with regionally re- 
current or metastatic thyroid cancer following a previous uni- 
lateral lobectomy for WDTC. Each patient in Group 2 under- 
went either debulking or complete removal of regionally 
recurrent WDTC along with a completion thyroidectomy. The 
histopathology of the initial thyroid specimens were reviewed 
by a pathologist at the UMMC and the diagnosis of WDTC was 
confirmed. Completion thyroidectomy was performed either 
within 7 days of the primary procedure or after a minimum of 3 
months. 
All completion thyroidectomies were performed using the 
following approach. The previous scar is excised and the 
midline between the strap muscles is opened. The isthmus is 
identified, and any residual pyramidal lobe is excised and 
included in the surgical specimen. The strap muscles are 
retracted laterally to allow adequate mobilization of the residual 
thyroid lobe. This lobe is removed in the manner previously 
described for total thyroid lobectomy [21]. Parathyroid glands 
are identified during the dissection and preserved. If there is 
any question regarding the viability of a parathyroid gland, it is 
sliced and implanted into the sternocleidomastoid muscle. All 
enlarged lymph nodes are also removed. Postoperatively, the 
patient's serum calcium is monitored daily for 3 days and then 
again on their return visit to the clinic 2 weeks later. Hypopara- 
thyroidism is defined as sustained symptomatic hypocaleemia. 
Hypoparathyroidism is considered permanent if the patient 
requires calcium and vitamin D supplements to maintain a 
normal serum calcium level for 6 months or longer, transient if 
the patient can be weaned off all supplements within 6 months. 
Recurrent laryngeal nerve (RLN) injury as a direct result of the 
completion thyroidectomy is characterized by hoarseness or 
loss of voice quality and is documented by either direct or 
indirect laryngoscopy. RLN palsy is defined as transient if there 
is documented proof of recovery of the RLN by laryngoscopy 
within 6 months of surgery. 
All patients (except those with Hfirthle cell carcinoma or the 
tall cell variant of papillary carcinoma) remained off thyroid 
hormone supplements following completion thyroidectomy in 
order to undergo a diagnostic thyroid scan using 2 mCi of 131I 
six weeks postoperatively. An ablative dose of 131I was  given if 
either the 24 hour percentage of uptake on the thyroid scan was 
>2% or there was uptake lateral the the thyroid bed, represent- 
Table 1. Histopathology of patients undergoing completion 
thyroidectomy. 
No. of pts. 
Histopathology Group 14 Group 2 b Total (%) 
Papillary 32 9 41 (68) 
Follicular 9 3 12 (20) 
Hfirthle 6 1 7 (12) 
"No evidence of residual disease. 
bEvidence of residual disease on exam. 
ing metastatic disease. Following the scan and any subsequent 
radioactive iodine ablative therapy, all patients were main- 
tained on thyroid hormone. The dose of thyroid hormone was 
adjusted so that the thyroid stimulating hormone (TSH) was 
suppressed to the lower limits of detection using a second 
generation TSH assay, and the patient remained clinically 
euthyroid. Patients were followed yearly with a clinical evalu- 
ation and measurement of serum thyroglobulin levels. 
All values are expressed as the mean -+ standard deviation. 
The Chi-square test was used to test for the significance of 
comparisons. 
Results 
From 1980 to 1991, 284 patients with WDTC were treated at the 
UMMC. Sixty patients who underwent an initial thyroid lobec- 
tomy for presumed unilateral WDTC subsequently underwent a 
completion thyroidectomy. The indication for the initial surgery 
was a solitary thyroid nodule in all 60 patients. There were 40 
females and 20 males. The average age was 37 --- 2.2 years 
ranging from 6 to 78 years. Two patients had a history of 
radiation exposure but neither proved to have thyroid cancer in 
the contralateral lobe. Forty-one (68%) patients had papillary 
cancer, 12 (20%) patients had follicular cancer, and 7 (12%) 
patients had Hfirthle cell carcinoma (Table I). 
The 60 patie0ts who underwent completion thyroidectomY 
were divided into two groups. Group 1 consisted of 47 patients 
without any evidence of regional recurrent or metastatic disease 
who underwent prophylactic completion thyroidectomy. The 
mean interval to completion thyroidectomy in Group 1 was 8.0 
--- 3.0 months with a range from 1 day to 108 months. In this 
group, 20 (43%) of 47 patients were found to have WDTC in the 
contralateral thyroid lobe. An additional 5 patients had unsus" 
pected positive cervical nodal disease. The positive nodes were 
found on the side opposite to the primary tumor in 4 of 5 
patients. Therefore, a total of 25 (53%) 'of the 47 patients with no 
evidence of disease clinically were found to have residual 
WDTC (Table 2). The majority of the contralateral tumors it~ 
this group, although not detected clinically, were >1.5 cm in 
size (Table 3). All bilateral cancer foci in Group 1 on histopa" 
thology were papillary carcinoma. Of the 6 patients with occult 
papillary carcinoma (<1.5 cm) found in the contralateral thY" 
roid lobe, 4 of these patients had either follicular or Hiirthle cell 
neoplasms in the primary lobe. 
Two patients from Group 1 developed recurrent disease 
following their completion thyroidectomy at 6 and 12 monthS, 
respectively. Both of these patients had residual disease at the 
time of early completion thyroidectomy (one with bilateral 
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Table 2. Residual disease found at prophylactic completion 
thyroidectomy (Group 1). 
Bilateral thyroid Nodal disease 
blistopathology (n) cancer only Overall 
Papillary (32) 15 5 20 
Follicular (9) 2 ~ 0 2 
bliirthle cell (6) 3" 0 3 
Total (47) 20 (43%) 5 (11%) 25 (53%) 
"Papillary carcinoma found in the contralateral lobe. 
n: Number of patients. 
Table 3. Size of lesions found in the contralateral thyroid lobe 
.~owing prophylactic completion thyroidectomy. 
Patients <1.5 cm >1.5 cm 
"--.. . . ._._, 
Group I ~ 6 14 
Gr., oup 2 b 0 12 
"No evidence of disease 
bEvidence of regional recurrence 
Table 4. Residual disease found in the contralateral thyroid lobe at 





Papillary (9) 8 (88) 
Follicular (3) 3 (100) 
bltirthle cell (1) 1 (100) 
Total (13) 12 (92) 
n: Number of patients. 
WDTC and the other with regional nodal disease). Both under- 
Went a third operation for excision of  their recurrent lateral 
nodal disease. All patients in Group 1 were alive without 
evidence of disease at last follow-up. The mean follow-up in this 
group was 58 + 8 months. Two patients were lost to follow-up 
at 28 and 21 'months, but were free of  disease when last seen. 
Group 2 consisted of 13 patients who presented with either 
regional recurrence (n = 12) or distant metastases (n = 1) and 
Underwent concurrent therapeutic completion thyroidectomy 
and excision or debulkment of  their recurrent disease. The 
mean time interval before therapeutic completion thyroidec- 
torny was 40 -+ 10 months ranging from 3 to 120 months. Twelve 
(92%) patients who presented with palpable regional recurrence 
had cancer in the remaining thyroid lobe (Table 4). Of the 8 
Patients in whom the primary lesion was papillary cancer, the 
COntralateral lesions were papillary cancer in 6 patients, tall cell 
Variant of papillary ,cancer in 1 patient, and 1 patient had 
.Undergone anaplastic transformation 120 months after the orig- 
inal lobectomy. In the patients in whom the primary tumor was 
either follicular or Hfirthle cell carcinoma, 2 patients had 
follicular carcinoma and 2 patients had Hfirthle cell carcinoma 
fOUnd in the remaining lobe. The 1 patient in this group who 
Presented with distant pulmonary metastases had no cancer 
found in the remaining thyroid lobe. The mean follow-up for 
Group 2 was 72 -+ 17 months. One patient died of  unrelated 
Causes, 4 patients are alive with evidence of thyroid cancer, and 
4 Patients are alive without evidence of thyroid cancer. Two 
patients died with extensive thyroid cancer and the remaining 
two patients have been lost to follow-up. 
Overall, 32 (53%) of  60 patients undergoing contralateral 
lobectomy for WDTC had residual tumor in the remaining 
thyroid lobe. If the 5 patients with cervical nodal disease are 
included, 37 (62%) of  60 patients had residual disease found at 
the time of  their completion thyroidectomy. There was no 
correlation between the size of  the primary tumor or the lymph 
node status and the occurrence of  cancer in the contralateral 
lobe. Of the 16 patients with multifocal disease in the primary 
lobe, 14 (88%) patients had cancer found in the contralateral 
lobe at completion thyroidectomy. Multifocal disease in the 
primary lobe was significantly better at predicting bilateral 
thyroid cancer then when it was not present (p < 0.01). 
Postoperative radioactive iodine thyroid scans were per- 
formed in 53 patients. The average percent uptake on t31I 
thyroid scintiscan was 1,.92 --+ 0.6%. Ablative therapy was 
administered to 26 (49%) of 53 patients, whose average percent 
uptake on thyroid ~3JI scan was 2.8 -+ 0.9%. The average 
percent uptake for those patients who did not receive 13tl 
ablative therapy was 0.57 - 0.1%. 
The overall postoperative complications included 3 (5%) 
patients with transient RLN palsy, 5 (8%) patients with tran- 
sient hypocalcemia, and 1 (1.7%) patient with permanent hypo- 
parathyroidism. The complications seen in Group 1 were 3 
patients with transient hypocalcemia and another 2 patients 
with transient RLN palsy. All of  these patients had resolution of 
their complication by the third postoperative month. There 
were no cases of permanent hypoparathyroidism or RLN injury 
in this group. Complications encountered in Group 2 consisted 
of transient hypocalcemia in 1 patient and transient RLN palsy 
in 2 patients. One patient with extensive regional recurrence 
developed permanent hypoparathyroidism. 
Discussion 
The treatment of WDTC remains controversial. The indolent 
course of most patients with WDTC makes the resolution of this 
controversy concerning the superiority of one mode of  therapy 
over the other difficult to assess. Many retrospective studies 
have supported the view that total or near total thyroidectomy 
results in a decreased recurrence rate [7, 8, 12-15], a decreased 
rate of  pulmonary metastases [10, 12], and improved survival 
compared to unilateral thyroid lobectomy [14, 15, 22]. How- 
ever, in many instances the ability to make the diagnosis of 
WDTC is not possible intra-operatively. This results in patients 
undergoing a lobectomy for what turns out to be WDTC. In 
these patients the questions arise as to whether any residual 
thyroid cancer remains in the neck and what is the safest way to 
remove the remaining thyroid lobe and possible remaining 
thyroid carcinoma. 
Most surgeons would agree that all thyroid cancer should be 
removed. The incidence of bilateral WDTC in the literature 
ranges from 25% to 88% [5, 11, 23-27], however, the signifi- 
cance of bilateral WDTC has been debated. Tollefsen and 
coworkers [26] demonstrated an incidence of occult (lesions 
< 1.5 cm) papillary carcinoma in the contralateral thyroid lobe 
in 38% of total thyroidectomy specimens, but only a 5% 
incidence of clinically recurrent carcinoma in the opposite lobe 
of patients who underwent a unilateral thyroid lobectomy for 
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papillary thyroid cancer. The incidence of recurrent thyroid 
cancer occurring in the residual contralateral lobe of the thyroid 
gland ranges in the literature from 4.7% to 46% (mean 7%) of 
such patients [28, 29]. These findings suggest that the high 
incidence of bilateral thyroid cancer may not always be clini- 
cally significant. 
In this series, all patients with regional recurrence following 
unilateral thyroid lobectomy had significant thyroid cancer in 
the remaining thyroid lobe. This raises the question whether 
regional recurrence may have been avoided with an initial total 
thyroidectomy. However, because of our practice at the 
UMMC, it is impossible to accurately assess this statement 
based on data from our patient population base. Our practice of 
performing completion thyroidectomy in all patients with clin- 
ically significant WDTC has resulted in a very small, non- 
representative cohort of patients who are being observed fol- 
lowing unilateral thyroid lobectomy for WDTC. However, Rose 
and associates [2] did follow 82 patients following thyroid 
lobectomy for WDTC and found in this group 30 patients who 
developed regional recurrence and 8 patients who developed 
distant metastases. Among these 38 (46%) patients, 27 went on 
to have a completion thyroidectomy. In 20 (74%) of these 27 
patients thyroid cancer was found in the remaining lobe. Among 
the remaining 7 patients who had no cancer found in the 
residual thyroid lobe, 5 patients presented with distant metas- 
tases. Rose and colleagues [29] also followed 34 patients who 
underwent prophylactic completion thyroidectomy. In this 
group, 21 (62%) of 34 patients had WDTC found in the contra- 
lateral lobe and an additional 3 patients had cervical nodal 
disease alone. Only 5 (15%) of these 34 patients developed 
recurrent disease following completion thyroidectomy and all 
but one was apparently cured following further surgical inter- 
vention. We observed a similar 4% recurrence rate in our 
comparable study group (Group 1). In Rose's series, the rate of 
recurrence following the initial unilateral thyroid lobectomy 
patients was 46% and was in keeping with the incidence of 
thyroid cancer found in the contralateral lobe (62%) found at 
prophylactic completion thyroidectomy. Contrary to the results 
reported by Tollefsen and coworkers [26], this raises the 
question whether the high incidence of thyroid cancer found in 
the contralateral lobe may be the source of some of the 
recurrences in patients following a unilateral thyroid iobectomy 
for WDTC. 
Unfortunately, the ability to clinically assess involvement of 
the contralateral lobe in the postoperative period is limited. In 
this series, although the majority of the contralateral tumors 
found at completion thyroidectomy (26 of 32) were >1.5 cm, 
they were not appreciated clinically by the original surgeon or 
at the time of their assessment for completion thyroidectomy. 
Other factors, such as the size of the primary tumor or lymph 
node involvement, were not found to be indicators of bilateral 
WDTC. The presence of multicentricity in the primary lobe was 
found to be associated with a higher incidence of bilateral 
thyroid cancer than when it was not present (p < 0.01). Others 
have also found that multiple foci in the primary lobe indicated 
bilateral disease in a significant number of patients [24, 30]. 
Since it has been shown that the incidence of unsuspected 
carcinoma is high, the question remains of the safest way to 
remove the remaining thyroid lobe in patients with WDTC who 
have undergone a unilateral lobectomy. Because reoperative 
thyroid surgery has been associated with a high morbidity [20, 
26], some surgeons and endocrinologist have advocated ~31I 
ablation of the remaining thyroid remnant in order to achieve a 
total thyroidectomy [31]. This approach, however, has several 
disadvantages. First, several doses of radioactive iodine may be 
necessary in order to achieve an adequate thyroid ablation [18]. 
Beierwaltes and associates [32] demonstrated that it is difficult 
to adequately ablate large thyroid remnants (>5% uptake). 
Second, there is an additional concern over the long-term 
affects of 13~I ablation of normal thyroid tissue causing second- 
ary injury to the adjacent parathyroid glands [33]. Bondesen 
and colleagues [33] reported a series of 10 parathyroid adeno- 
mas that developed in patients who received ~31I ablation of 
their thyroid. The authors concluded that this was not mere 
coincidence. They further suggested that the use of radioactive 
iodine to ablate significant amounts of thyroid tissue, especially 
in the younger age group, is a risk factor for the subsequent 
development of parathyroid adenomas. Because of these con- 
cerns with the use of 1311 to ablate the remaining thyroid lobe, 
surgical resection remains the best way of removing the remain- 
ing thyroid tissue. The concerns about increased morbidity with 
more than a thyroid lobectomy are not necessarily justified. Irl 
experienced hands, total thyroidectomy, and more importantly 
secondary thyroid operations, can be performed safely with 
little morbidity to the patient [9, 13, 24, 25, 27, 34]. Calabro and 
coworkers, [24] in a recent review of completion thyroidecto" 
mies, reported an incidence of transient hypocalcemia of 129~ 
and transient RLN palsy of 1.5%. In our series the incidence of 
transient hypocalcemia was 8% and transient RLN palsy was 
5%. Only 1 patient had permanent hypoparathyroidism, hoW- 
ever, this was in a patient with extensive regional recurrence 
who underwent extensive debulking concurrent with a thera" 
peutic completion thyroidectomy. 
Ideally, there should be little need for completion thyroidec" 
tomy in situations where total thyroidectomy is routinely per- 
formed for clinically significant WDTC. Papillary carcinoma 
can usually be diagnosed with certainty in most cases by fine 
needle aspiration cytology or frozen section. Occasionally the 
encapsulated follicular variant may be difficult to diagnosis until 
permanent sections can be performed. A much more common 
problem is the well-dilterentiated encapsulated follicular or 
Hiirthle cell neoplasm which is diagnosed as carcinoma only 
after permanent sections have demonstrated microscopic cap" 
sular or vascular invasion. In order to decrease the need for 
completion thyroidectomy, we have in the past few yearS 
performed total thyroidectomy for all such neoplasms >4 cm in 
diameter because our previous studies showed approximately 
80% of these tumors proved to be malignant after permanent 
microscopic study [35]. Because smaller follicular carcinomas 
rarely if ever are multicentric, rarely spread within the lymphat" 
ics, and rarely require 13~I for treatment of distant metastaseS, 
it is debatable whether this small subgroup requires completiota 
total thyroidectomy. In this series 2 of 9 follicular carcinoma 
patients in Group 1 had a bilateral foci of cancer. However, irt 
both patients, papillary carcinoma <1.0 cm was found in the 
contralateral lobe. 
Although many surgeons advocate total or near-total thyroid" 
ectomy for WDTC, some of these surgeons hesitate to do 
completion thyroidectomies when there is no clinical evidence 
to suggest bilateral disease, for fear of the added morbidity to 
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the patient. This series, however ,  demonstrates  that completion 
thyroidectomy can be performed safely with little morbidity to 
the patient.  The high incidence (43%) of thyroid carcinoma in 
the residual thyroid lobe in patients with no clinical evidence of  
disease following unilateral lobectomy suggests the necessity 
for re-operat ive intervention to eliminate an unsuspected con- 
tralateral focus of cancer.  Fur thermore,  patients with regional 
recurrence in whom a significant amount of  thyroid tissue 
remains should undergo completion thyroidectomy along with 
treatment of  their  recurrent  disease as there appears to be a high 
percentage of residual thyroid carcinoma in the remaining 
thyroid lobe. Finally,  multicentricity in the primary lobe was 
associated with bilateral thyroid disease and may be used as a 
guided in assessing patients for completion thyroidectomy.  
R~sum~ 
Le but de cette 6tude 6tait d '6valuer  l '6volution chirurgicale 
apr~s thyroidectomie totale des patients ayant  un cancer  thy- 
to'Mien pr6sum6 bien diff6renci6 et unilat6ral (CTBD). Les 
donn6es m6dicales de tous les  patients ayant  eu une lobectomie 
Unilat6rale de la thyro'ide pour CTBD et qui ont eu secondaire- 
ment une totalisation de la thyroidectomie ont 6t6 revues. Entre 
1980 et 1991, 60 patients ayant  un CTBD ont eu une totalisation 
de la thyroidectomie,  quarante sept avaient un CTBD pr6sum6 
Unilat6ral, sans argument pour une pathologic r6siduelle avant  
la totalisation de la thyroidectomie (groupe 1). Vingt cinq 
d 'entre eux (53%) se sont av6r6s avoir  un reliquat n6oplasique 
Persistant au niveau de la r6gion cervicale.  Chez 20/47 (43%) 
Patient s, on a retrouv6 un foyer de cancer  dans le lobe restant 
de la thyroide.  Chez 5 patients suppl6mentalres il n ' a  pas 6t6 
retrouv6 de cancer  dans le lobe controlat6ral mais une dystro- 
Phic nodulaire non suspecte.  Les  13/60 patients restants pr6- 
sentaient Soit une r6cidive r6gionale (12) soit des m6tastases 
distance (1) au moment de la totalisation de la thyroidectomie 
(groupe 2). T o u s l e s  patients du groupe 2 sauf un (92%) avaient 
un cancer dans le lobe restant.  Une atteinte plurifocale dans le 
Premier lobe 6tait associ6e avec l 'existence d 'un cancer  bilat- 
6ral (p < 0.01). Les complications ont 6t6 rares: une hypocal-  
C6rnie transitoire est survenue chez 5 (8%) patients,  une hy- 
poparathyroidie d6finitive est apparue chez 1 (1.7%) patient. 
Une paralysie r6curentielle transitoire a 6t6 retrouv6e chez 3 
(5%) patients.  Conclusions: Un reliquat de TCBD a 6t6 retrouv6 
chez 37/60 (62%) patients op6r6s d 'une  totalisation de thyroi- 
dectomie. L 'a t te in te  multifocale dans le premier  lobe r6s6qu6 
~tait associ6e avec une incidence 61ev6e de cancer  thyroidien 
Controlat6ral. La  totalisation de la thyroidectomie est une 
13roc6dure sans risque qui pent pr6venir le d6veloppement 
d'une r6cidive r6gionale en 61iminant un foyer  de cancer  non 
SUspect6. 
Resumen 
E1 prop6sito del presente estudio fue valorar el resultado 
quirt~rgico de completar  a una t iroidectomfa total ia resecci6n 
tiroidea real izada en pacientes con c~incer presumiblemente 
Unilateral y bien diferenciado de la gl,-lndula tiroides (CTBD). Se 
revisaron las historias clinicas de todos los pacientes sometidos 
.a lobectomfa t iroidea unilateral por  CTBD, en quienes subsigu- 
~entemente se complet6 la t iroidectomia,  procedimiento que fue 
realizado en 60 pacientes con CTBD en el perfodo 1980--1991. 
Cuarenta y siete pacientes tenian CTBD presumiblemente 
unilateral, sin evidencia de enfermedad residual antes de com- 
pletarse la t iroidectomfa (grupo 1); en veinticinco (53%) de 
estos pacientes se hall6 neoplasia residual en el cuello. En 20/47 
(43%) pacientes se encontr6 un foco de c~tncer en el 16bulo 
tiroideo remanente y en 5 casos adicionales aunque no se 
encontr6 c~incer en el 16bulo contralateral ,  se hall6 extensi6n 
ganglionar no sospechada.  Los  13/60 pacientes restantes pre- 
sentaron recurrencia (12) o met~istasis distantes (1) en el mo- 
mento de completarse la t iroidectomfa (grupo 2). Todos los 
pacientes del grupo 2, excepto I (92%), presentaban c~incer en 
el 16bulo remanente.  La  presencia  de enfermedad multifocal en 
el 16bulo primario apareci6 asociada con cfincer t iroideo bilat- 
eral (p < 0.01). Las complicaciones fueron raras;  se present6 
hipocalcemia transitoria en 5 (8%) pacientes,  hipotiroidismo 
permanente en 1 (1.7%) y par~ilisis parcial y transi toria del 
nervio larfngeo recurrente en 3 (5%). Conclusiones:  Se en- 
contr6 CTBD en 37/60 (62%) pacientes en quienes se complet6 
la tiroidectomfa. La  presencia  de enfermedad multifocal en el 
16bulo primario resecado apareci6 asociada con una alta inci- 
dencia de cfincer contralateral .  E1 procedimiento de completar  
la t iroidectomfa aparece como una operaci6n segura que puede 
prevenir  el desarrollo recurrencia regional al eliminar focos 
insospechados de c,Sncer. 
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Invited Commentary 
P r o f e s s o r  T h o m a s  S. R e e v e  
Department of Surgery, University of Sydney, Sydney, Australia 
Conventional wisdom has it that to come to a sound conclusion, 
the matter  at hand should be duly considered,  data collected, 
data analyzed,  conclusions drawn, and decisions made. How 
often this process  has been followed in relation to thyroid 
cancer is difficult to estimate.  However ,  it is clear that the 
decisions that have been made to date result in controversy.  
There are a number of  contradictory opinions as to what should 
be done and opinion in surgery in such controversial  areas is 
difficult to resolve by logic alone. This paper  makes a significant 
contribution towards a resolution, particularly for patients 
having had a lobectomy as prime treatment  for well differenti- 
ated thyroid cancer  (WDTC). 
The problem Seems to be that after t reatment for WDTC 
patients generally do well, therefore,  it is widely believed that 
minimal surgery will suffice for optimal results. This premise 
has not always been addressed in clearly logical terms and 
insufficient attention appears to have been given in the reporting 
of  results as they relate to those few who die from the disease 
or who suffer multiple surgical operations for recurrence. 
The report  by Pasieka and colleagues shows that significant 
residual cancer  is present  in the contralateral  lobe (43%) when 
lobectomy is done as prime treatment.  The presence of WDTC 
in 62% of  patients undergoing complet ion thyroidectomy pro- 
vides a strong argument for further exploration when WDTC is 
discovered in a lobar lesion, especial ly when the lesions in the 
lobe are multifocal. Low morbidity surgery such as outlined in 
the paper  further supports  this approach.  Although the residual 
tumor may well not kill the patients,  to leave cancer  in place, 
particularly when amenable to excision, is against all surgical 
principles. It can hardly be argued that cancer  is good for 
patients,  even when of more the favorable diploid status [1]. 
When cancer  is in both thyroid lobes o r  significantly suspected 
of being in both, part icularly if as Pasieka and coworkers  have 
shown, the disease is multifocal in the excised lobe, total 
thyroidectomy should be done as the authors propose.  
This paper  clearly identifies that surgery which eradicates the 
whole gland is the optimal form of t reatment  for this type of 
malignancy. This supports the recent  report  by DeGroot  and 
coworkers [2] and clearly suggests that patients with WDTC 
treated by total or near total thyroidectomy have an improved 
survival and decreased recurrence of their disease. 
While the authors do not offer contralateral  lobectomy for 
patients with tumors <1 cm in size, they advocate  surgery for 
co-existent or recurrent  disease where clinically possible.  It is 
